Long-term maintenance therapy with calcineurin inhibitors: An update

Transplantation Proceedings

Volumn 42, Issue 9 SUPPL., 2010, Pages

  Campistol, J M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SHORT COURSE THERAPY;

EID: 78649410631     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.09.015     Document Type: Article

References (23)

1. RapamuneSummary of Product Characteristics (SPC). Wyeth Pharmaceuticals
2. R.E. Morris Mechanisms of action of new immunosuppressive drugs Ther Drug Monit 17 1995 564
3. J.M. Morales, L. Wramner, and H. Kreis Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients Am J Transplant 2 2002 436
4. C. Castro, J.M. Campistol, and D. Sancho Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway Atherosclerosis 172 2004 31
5. H.M. Kauffman, W.S. Cherikh, and Y. Cheng Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883
6. C.A. Benavides, V.B. Pollard, and S. Mauiyyedi BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes Transplantation 84 2007 83
7. A.S. Macdonald Management strategies for nephrotoxicity Transplantation 69 12 suppl 2000 SS31
8. Y. Lebranchu, A. Thierry, and O. Toupance Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study Am J Transplant 9 2009 1115
9. S.J. Knechtle, J. Pascual, and D.D. Bloom Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring Am J Transplant 9 2009 1087
10. F.P. Schena, M.D. Pascoe, and J. Alberu Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
11. B.D. Kahan Rapamune US Study Group Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study Lancet 356 2000 194
12. A.S. MacDonald Rapamune Global Study Group: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts Transplantation 71 2001 271
13. R.W.G. Johnson, H. Kreis, and R. Oberbauer Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure Transplantation 72 2001 777
14. S.M. Flechner, D. Goldfarb, and K. Solez kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs Transplantation 83 2007 883
15. R. Oberbauer, G. Segoloni, and J.M. Campistol Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation Transplant Int 18 2005 22
16. A.O. Gaber, B.D. Kahan, and C. Van Buren Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial Transplantation 86 2008 1187
17. B.D. Kahan, R. Knight, and L. Schoenberg Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston Experience Transplant Proc 35 suppl 3A 2003 25S
18. H. Podder, and B.D. Kahan Individualization of immunosuppressive therapy: I Sirolimus improves outcomes in African-American renal transplant recipients Transplant Proc 37 2005 3723
19. S.E. Woodle, F. Vincenti, and M.I. Lorber A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus Am J Transplant 5 2005 157
20. L. Demopoulos, M. Polinsky, and G. Steele Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials Transplant Proc 40 2008 1407
21. S. Vitko, Z. Wlodarczyk, and L. Kyllnen Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study Am J Transplant 6 2006 531
22. O. Johnston, C.L. Rose, and A.C. Webster Sirolimus is associated with new-onset diabetes in kidney transplant recipients J Am Soc Nephrol 19 2008 1411
23. V.C. McAlister, K. Mahalati, and K.M. Peltekian A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration Ther Drug Monit 24 2002 346